
The European Union’s medicines regulator is reversing course on its decision to block a new Alzheimer’s disease treatment, saying the drug can be offered to certain patients under strict safety protocols.
In late March, the European Medicines Agency’s (EMA) drug evaluators said the risks did not outweigh the benefits for the medicine donanemab, which can slow the progression of early-stage Alzheimer’s but also raises the risk of potentially deadly brain swelling and bleeding.